|
||
Deflazacort Tarbis Pregnancy |
||
Deflazacort Tarbis crosses the placenta. Orofacial clefts, intrauterine growth restriction, and decreased birth weight have been reported following maternal use. Hypoadrenalism may occur in newborns following maternal use of corticosteroids in pregnancy; monitor.
Corticosteroids have been detected in breast milk in low amounts, however, specific information on this drug in breast milk is unknown. Theoretically, the presence of exogenous corticosteroids in breast milk could suppress growth, interfere with endogenous corticosteroid production, or cause other unwanted effects in breast fed babies, but in doses of up to 50 mg per day, this drug is unlikely to produce a degree of adrenal suppression that would affect the breastfed infant. Higher doses may be expected to affect the degree of adrenal suppression and should be used with caution. There are no data on the effects on milk production.
Benefit should outweigh risk Excreted into human milk: Unknown Comments: Doses of up to 50 mg daily are unlikely to cause systemic effects in the breastfed infant.
See references
There are no reviews yet. Be the first to write one! |
Information checked by Dr. Sachin Kumar, MD Pharmacology
|